Revenue of Perjeta 2018-2022
In 2022, cancer therapy Perjeta's sales reached 4.42 billion U.S. dollars, marking a 3.3 percent rise from 2021. The highest growth in Perjeta's revenue over the period of five years occurred in 2019, with a 27 percent increase compared to the previous year, 2018. This statistic depicts the total revenue of Roche's Perjeta worldwide from 2018 to 2022.